Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Civetta Therapeutics

Explore full profile

Civetta Therapeutics is a cancer therapeutics company to advance new medicines through small molecule targeting of beta-propeller domains

Cambridge, United StatesFounded 2019Biotech & Life Sciences
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Civetta Therapeutics and the history behind them.

About Civetta Therapeutics

Civetta Therapeutics is a biotechnology startup focused on developing innovative treatments by targeting protein-protein interactions. Proteins are essential molecules in the body that control various biological processes, and their interactions can influence disease progression. Civetta aims to unlock the therapeutic potential of these interactions, which have traditionally been difficult to target with drugs.

Read full description

The company operates in the biopharmaceutical market, primarily serving clients in the healthcare and medical research sectors. This includes pharmaceutical companies, research institutions, and potentially healthcare providers looking for advanced treatment options.

Civetta's business model revolves around research and development (R&D) of new drugs. They identify specific protein complexes associated with diseases and develop small molecules that can precisely target these complexes. By doing so, they aim to create highly specific treatments that can intervene in disease processes without affecting other functions in the body.

Revenue generation for Civetta comes from multiple streams. Primarily, they earn money through partnerships and collaborations with larger pharmaceutical companies that are interested in their innovative approaches. Additionally, they may receive funding from grants and research institutions, as well as potential future earnings from the commercialization of their developed therapies.

In summary, Civetta Therapeutics is pioneering new ways to treat diseases by focusing on the intricate interactions between proteins. They serve the biopharmaceutical market with a business model centered on R&D and strategic partnerships, aiming to create precise and effective treatments.

Source: Dealroom company data

At a glance

Founded
2019
Headquarters
Cambridge, United States
Sector
Biotech & Life Sciences

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Deerfield
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Civetta Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Civetta Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.